SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Graham Corporation disclosed its results of operations and financial condition for the fourth quarter and fiscal year ended March 31, 2026 via a press release furnished as Exhibit 99.1, with accompanying presentation slides and supplemental data tables (historical sales, orders, and backlog) posted for an earnings conference call and webcast on June 8, 2026.
View raw filing on EDGAR →The filing discloses financial results for the three months ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is material to investors as it provides periodic financial performance data essential to assessing the registrant's operational and financial condition.
View raw filing on EDGAR →The filing discloses financial results for the fiscal first quarter ended April 30, 2026, via a press release attached as Exhibit 99.1. This is a standard quarterly earnings release under Item 2.02, which is material to investors as it provides periodic financial performance data essential to assessing the registrant's condition.
View raw filing on EDGAR →Tango Therapeutics disclosed initial safety and efficacy data from a Phase 1/2 combination trial of vopimetostat with RAS(ON) inhibitors, demonstrating strong efficacy signals (92% ORR in PDAC with daraxonrasib, 52% ORR with zoldonrasib) and favorable safety profiles. This clinical milestone data, which will advance the program to Phase 3 development, is material to investors' assessment of the company's pipeline and regulatory prospects.
View raw filing on EDGAR →Village Farms entered into securities purchase agreements on June 5, 2026 for a registered direct offering of 7,500,000 common shares at US$2.00 per share, generating approximately US$15 million in gross proceeds. This is a registered equity issuance that will dilute existing shareholders' ownership and is material to investors assessing the company's capital structure and financing activities.
View raw filing on EDGAR →Strategy Inc sold 1,409,600 shares of Class A Common Stock under its at-the-market offering program during June 1-7, 2026, generating $181.0 million in net proceeds, with $25.956 billion remaining capacity under a $21.0 billion offering increase announced on March 23, 2026.
View raw filing on EDGAR →Fair Isaac entered into a material amendment to its credit agreement on June 5, 2026, adding a $1.5 billion unsecured incremental term loan maturing in 2028, with proceeds designated for an accelerated share repurchase program.
View raw filing on EDGAR →Fair Isaac announced a new $2.0 billion stock repurchase program and entered into a $1.5 billion accelerated share repurchase (ASR) agreement with Wells Fargo Securities, with an upfront payment on June 8, 2026.
View raw filing on EDGAR →Paul Carreiro was appointed as President and Chief Executive Officer effective July 6, 2026, with a $500,000 base salary, performance bonus eligibility, and substantial equity grants including 1.06 million LTIP Units.
View raw filing on EDGAR →A material commercial customer is terminating two contracted projects effective June 16, 2026, reducing annual recurring revenue by $2.7 million (73% of that customer's $3.7 million prior ARR), though the company is pursuing mitigation measures and recertification opportunities.
View raw filing on EDGAR →The filing discloses results of a stockholder vote at the 2026 Annual Meeting of Stockholders held on June 8, 2026, where shareholders approved an amendment to the terms of the STRC preferred stock to change dividend payment frequency from monthly to semi-monthly. This is a shareholder vote result on a material corporate action affecting preferred stock terms.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Ambiq Micro's 2026 Annual Meeting held on June 8, 2026, reporting final voting tallies for two proposals: election of Class I directors (Timothy Chen and Ker Zhang, Ph.D.) and ratification of KPMG LLP as independent auditor. The filing directly matches Item 5.07 requirements and is material to investors as it documents stockholder approval of board composition and audit firm selection.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the June 5, 2026 Annual Meeting of Stockholders, reporting the outcomes of three proposals: election of three Class II directors (Jane Chung, Connie Matsui, and James Panek), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The tabulated voting results with shares for, against, withheld, and abstaining are the hallmark of Item 5.07 disclosure and constitute material information about corporate governance actions.
View raw filing on EDGAR →Vor Biopharma announced that its partner RemeGen received conditional approval from China's NMPA for telitacicept in IgA nephropathy and full approval in Sjögren's disease. This represents a material regulatory milestone for a product in the company's pipeline, affecting investor assessment of the company's commercial prospects and partnership value. However, the event does not fit neatly into the standard taxonomy categories (not an earnings release, M&A activity, or executive change), warranting classification as other_material.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Red Rock Resorts' Annual Meeting of Stockholders held on June 4, 2026. The filing reports voting outcomes for three proposals: election of five directors (Frank J. Fertitta III, Lorenzo J. Fertitta, Robert A. Cashell Jr., Robert E. Lewis, and James E. Nave), a say-on-pay advisory vote, and ratification of Ernst & Young LLP as independent auditor. All proposals passed with majority support, making this a material disclosure of shareholder meeting outcomes required under Item 5.07.
View raw filing on EDGAR →Mastercard completed a $5 billion debt offering across five tranches of notes with varying maturities and rates (2028–2036). While this is a material financing event affecting the company's capital structure and liquidity, it does not fit neatly into the standard 8-K taxonomy. The disclosure is routine debt issuance under an existing S-3 registration statement, not a covenant breach, going-concern issue, or other acute financial stress signal. Classified as other_material because the magnitude and nature of the transaction would affect a reasonable investor's assessment of the company's financial position, but the event itself is a standard capital markets transaction rather than a discrete material event type.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the final voting results from CG Oncology's June 4, 2026 Annual Meeting of Stockholders, including four proposals: election of two Class II directors (Christina Rossi and Victor Tong, Jr.), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. The disclosure presents detailed vote tallies for each matter, which is the core content of Item 5.07 shareholder vote results.
View raw filing on EDGAR →The board awarded success bonuses totaling $450,000 to four named executive officers (Douglas Kaye, David Johnson, Timothy Donnelly, and Shirin Khosravi) in recognition of their role in restructuring the Company's debt.
View raw filing on EDGAR →The Company held its 2026 Annual Meeting of Stockholders on June 3, 2026, with voting results reported for four proposals: election of seven directors (all elected with majority support), ratification of Deloitte Touche LLP as independent auditor, advisory vote on executive compensation frequency (1-year preference), and advisory approval of executive compensation policies.
View raw filing on EDGAR →Vince Holding Corp. held its 2026 Annual Meeting on June 4, 2026, with shareholders voting on four proposals: election of Class III director Michael Mardy, ratification of PricewaterhouseCoopers as auditor, advisory approval of named executive officer compensation, and approval of an amendment to the stock plan increasing authorized shares by 1,000,000. The filing reports the tabulated vote counts for each proposal.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Beam Therapeutics' June 3, 2026 annual meeting, covering three proposals: election of Class III directors (John Evans, John Maraganore, and Christi Shaw), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. The filing directly matches Item 5.07 requirements and presents tabulated vote counts for each proposal.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of Dyne Therapeutics' 2026 Annual Meeting of Stockholders held on June 5, 2026, including votes on director elections (David Lubner, Brian Posner, Jason Rhodes), advisory compensation approval, authorization of additional common shares (200M to 400M), officer exculpation amendment, and auditor ratification. The filing presents tabulated voting results for each matter, which is the core disclosure required under Item 5.07 for shareholder vote results.
View raw filing on EDGAR →Jeremy Chadwick, Chief Operating Officer, resigned effective June 5, 2026, for personal reasons. The disclosure centers on the departure of a named executive officer from a C-suite position, which is material to investors assessing management continuity and operational leadership. While he remains as an advisor through November 2026, the principal event is his resignation from the COO role.
View raw filing on EDGAR →Equity Residential disclosed compensatory arrangements for four named executives (Schall, Manelis, O'Shea, and Fenster) in connection with the pending Equity Residential–AvalonBay merger, including base salaries, cash and equity incentive targets, long-term performance-vesting awards, and one-time transaction awards.
View raw filing on EDGAR →Equity Residential announced the closing of its combination with AvalonBay and the formation of a new executive leadership team for the combined entity.
View raw filing on EDGAR →Climb Bio held its Annual Meeting of stockholders on June 8, 2026, with voting results on multiple proposals: election of directors Alexander Cumbo and Douglas Williams, ratification of PricewaterhouseCoopers LLP as auditor, rejection of a director removal for cause amendment, and approval of the 2021 Equity Incentive Plan Amendment to include prefunded warrants in the automatic share pool increase mechanism.
View raw filing on EDGAR →Hubbell Inc. announced a $1.9 billion debt offering to fund in part the previously announced acquisition of NSI Electrical Buyer, Inc. (NSI Industries). The debt issuance is integral to the M&A transaction, serving as the primary financing mechanism for the acquisition.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder voting results from First Advantage's June 5, 2026 Annual Meeting of Stockholders. The filing reports final vote tallies for three proposals: election of Class II directors (James L. Clark, Bridgett R. Price, Mark Gillett), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, and the disclosure is material as it documents the outcome of the annual shareholder meeting and confirms board composition and auditor appointment.
View raw filing on EDGAR →This Item 5.07 disclosure reports the final results of Bumble Inc.'s 2026 Annual Meeting of Stockholders held on June 4, 2026, including voting outcomes on three proposals: election of three Class II directors (R. Lynn Atchison, Amy M. Griffin, and Sissie L. Hsiao), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing provides vote tallies certified by the independent inspector of election, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →ATI Inc. completed a $450 million offering of unsecured senior notes due 2033 on June 8, 2026, pursuant to a shelf registration statement. The notes carry a 5.875% coupon and represent a material financing activity and capital structure change.
View raw filing on EDGAR →Robert Lutz was appointed as Chief Financial and Operating Officer effective July 15, 2026, following David Lowrance's resignation due to health reasons. Lutz's compensation package includes a base salary of $510,000 and equity grants of options and RSUs.
View raw filing on EDGAR →Stockholders approved an amendment to the certificate of incorporation to increase authorized common shares from 300 million to 600 million, doubling the company's equity issuance capacity.
View raw filing on EDGAR →Savara held its annual meeting of stockholders on June 4, 2026, at which shareholders elected six board directors and approved four proposals including a certificate amendment, equity plan increase, auditor ratification, and an advisory vote on executive compensation.
View raw filing on EDGAR →Cerus Corporation entered into amended and restated credit agreements on June 5, 2026, refinancing its existing term and revolving loan facilities with MidCap Financial Trust and MidCap Funding IV Trust. The new facilities comprise a $65 million term loan (with $35 million borrowed at closing) and a $30 million revolving credit facility, representing a material restructuring of the Company's debt capital structure.
View raw filing on EDGAR →Albert A. Manzone was appointed as Interim President and CEO following the departure of Patrick Lockwood-Taylor. The Board has initiated a comprehensive search process for a permanent CEO.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Four Corners Property Trust's June 4, 2026 annual meeting of stockholders. The filing presents final voting tallies for three proposals: election of eight directors, ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. Item 5.07 is the designated 8-K item for shareholder vote results, and the prose directly reports the vote counts and outcomes for each proposal.
View raw filing on EDGAR →Jesse A. Coury's resignation as Chief Financial Officer effective June 30, 2026, is the principal disclosed action. While the filing also announces Eric R. Nielsen's appointment as interim CFO, the core event centers on the departure of the CFO. The filing explicitly states the resignation is unrelated to any disagreement, and Nielsen's appointment is characterized as interim pending a permanent replacement, making the departure the more salient event.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from Paymentus Holdings' 2026 Annual Meeting held on June 5, 2026. The filing reports voting outcomes on four matters: election of three Class II directors (Jody Davids, Adam Malinowski, and Gary Trainor), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, and advisory vote on say-on-pay frequency (one year). The detailed vote tallies and high participation rate (97% of voting power present) are material to investors assessing board composition and governance.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Duluth Holdings' June 3, 2026 annual meeting, covering three proposals: election of eight directors, advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor. The filing presents detailed vote tallies by share class for each proposal, which is the quintessential content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →Liftoff Mobile completed its initial public offering on June 3, 2026, entering into material definitive agreements including a Registration Rights Agreement and Stockholders Agreements with major investors Blackstone and General Atlantic as part of the IPO transaction.
View raw filing on EDGAR →Liftoff Mobile completed a registered public offering of 21,850,000 shares of common stock at $23.00 per share, raising $472.4 million in net proceeds, with proceeds used to repay debt and for general corporate purposes.
View raw filing on EDGAR →The Board and stockholders approved and adopted the 2026 Omnibus Incentive Plan and the 2026 Employee Stock Purchase Plan, both effective June 3, 2026, establishing the company's post-IPO equity compensation framework.
View raw filing on EDGAR →The filing discloses a material modification to rights of security holders, with substance incorporated by reference from Item 5.03, relating to the company's post-IPO capital structure and governance.
View raw filing on EDGAR →Jaguar Health held its 2026 Annual Meeting of Stockholders on June 8, 2026, with shareholders voting on five proposals including election of a Class II director, ratification of auditors, and approval of dilutive issuances to C/M Capital Master Fund representing more than 19.99% of outstanding shares under two separate agreements (ELOC and Preferred Stock Purchase Agreement).
View raw filing on EDGAR →The filing discloses a press release reporting financial results for the three months ended April 30, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard quarterly earnings release, which is material to investors as it provides periodic financial performance data essential to assessing the registrant's operational and financial condition.
View raw filing on EDGAR →Palladyne AI Corp. held its Annual Meeting on or before June 8, 2026, with shareholders voting on four proposals: election of Class II director Dennis Weibling, ratification of KPMG LLP as independent auditor, approval of an amendment to the 2021 Equity Incentive Plan increasing available shares by 4,500,000, and approval of restricted stock unit awards totaling 5,360,659 shares to senior executives.
View raw filing on EDGAR →West Bay BDC LLC disclosed an unregistered sale of approximately 2.1 million common units for $37.1 million under Item 3.02, relying on Section 4(a)(2) and Regulation D exemptions. This is a classic dilutive private placement to existing investors via capital drawdown notices under subscription agreements, representing a material capital raise that would affect investor assessment of ownership dilution and the company's capital structure.
View raw filing on EDGAR →International Battery Metals Ltd. announced financial and operational results for the fourth quarter and full fiscal year 2026 ended March 31, 2026, disclosed via press release furnished as Exhibit 99.1.
View raw filing on EDGAR →This Item 5.07 filing discloses the final voting results from NeuroPace's June 5, 2026 Annual Meeting of Stockholders, including the election of Class II directors (Lisa Andrade and Scott Huennekens) and ratification of PricewaterhouseCoopers LLP as the independent auditor. The disclosure presents vote tallies (For, Against, Withhold, Abstain, Broker Non-Votes) for each proposal, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →MSGE announced entry into a non-binding memorandum of understanding with Penn Station's Master Developer regarding potential transfer of the Infosys Theater at MSG and redevelopment coordination, contingent on execution of definitive agreements. While the MOU is non-binding and completion is uncertain, the disclosure involves a significant real estate transaction affecting MSG's operations and asset portfolio that would materially affect investor assessment of the company's strategic direction and asset base.
View raw filing on EDGAR →